-
08:30
-08:50
*The four epidemiological stages in the global evolution of inflammatory bowel disease
-
08:50
-09:10
*The burden of inflammatory bowel disease in Europe in the 2020s
-
09:10
-09:30
Emerging treatment option and strategies for inflammatory bowel disease: the state of the art
-
09:30
-09:45
(BA01) Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from U-ACHIEVE study
-
09:45
-10:00
*(BA02) Guselkumab induction therapy effect on endoscopic outcome measures in moderately-to-severely active Crohn’s disease patients: week-12 results from phase-2 GALAXI-1 study
Leading Forum The growing era of inflammatory bowel disease
